Use of selective medium for Burkholderia cepacia isolation in respiratory samples from cystic fibrosis patients

Abstract

SUMMARYBurkholderia cepacia colonizes cystic fibrosis (CF) patients. We evaluated the impact of the use of a selective medium in the rate of B. cepacia recovery from respiratory samples of CF patients. During a 6-month period, respiratory samples were collected from 106 CF patients and cultivated on selective media including a B. cepacia selective medium. Confirmation of the identity of B. cepacia isolates was carried out by species specific PCR and determination of genomovar status performed by a sequential PCR approach. Results of B. cepacia isolation during this period were compared to the preceding two years, when the sample processing was identical except for the lack of the B. cepacia selective medium. B. cepacia was isolated in 11/257 (4.2%) of the samples using the selective medium, in contrast with the preceding two years, when it was isolated in 6/1029 samples (0.58%), p < 0.0001. Identity of all 11 isolates was confirmed by PCR and genomovar determination was accomplished in all but one isolate. These results suggest that the use of a selective medium increases recovery rate of B. cepacia from respiratory samples.

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance

“…A standardized and low-cost medium designed to selectively grow medically important pathogens, such as P. aeruginosa or B. cepacia, has been recommended by various authors [8,9]. However, no selective medium for improved detection of S. maltophilia has yet been recommended by international guidelines, nor is such a medium yet commercially available.…”

“…Using selective media for the detection of medically important or rare pathogens such as P. aeruginosa, Burkholderia cepacia, or Scedosporium spp. has been shown to increase the isolation rates [8][9][10]. S. maltophilia exhibits an inherently resistant profile against a plethora of antibiotic agents.…”

Nosocomial bloodstream infections with Burkholderia stabilis

“…1,27 For detection of B. cepacia, the use of selective media containing colistin, ticarcillin, gentamicin, vancomycin and bacitracin is a critical first step in sample processing. 28,29 Definitive identification of the genomovars of the B. cepacia complex by routine methods of clinical microbiology and commercial, semi-automated systems is unreliable. 30 Confirmation of the tentative biochemical identification as B. cepacia complex and determination of the genomovar status has to be carried out by species-specific PCR.…”

Genomovar status, virulence markers and genotyping of Burkholderia cepacia complex strains isolated from Brazilian cystic fibrosis patients

“…Isolates identified as B. cepacia complex were submitted to DNA extraction as described elsewhere [8], and DNA was quantified in an ultraviolet spectrophotometer (BioPhotometer 6131, Eppendorf AG, Hamburg, Germany).…”

“…There is little published data regarding prevalence and genomovar distribution of B. cepacia complex strains isolated from Brazilian cystic fibrosis patients [8][9][10]. The Pediatric Pulmonology Unit of Instituto da Criança is one of the referral centres for CF care in Brazil and, although segregation of patients based on respiratory colonization has not been implemented to date, cross-colonization with P. aeruginosa strains has not been identified among patients [11].…”